An announcement from Genmab ( (GMAB) ) is now available.
On May 2, 2025, Genmab announced its plan to submit a supplemental Biologics License Application (sBLA) to the U.S. FDA for the combination of epcoritamab with rituximab and lenalidomide in treating relapsed/refractory follicular lymphoma. This decision follows positive interim results from the Phase 3 EPCORE FL-1 trial, which demonstrated a significant overall response rate. The move underscores Genmab’s commitment to advancing novel treatments in collaboration with AbbVie, potentially enhancing its position in the oncology market.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance, robust earnings call, and attractive valuation drive a high overall score. The stock’s technical indicators point to moderate upward momentum, but potential overbought conditions warrant caution. Key risks include dependency on major products and competitive pressures.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, the company leverages next-generation antibody technology platforms to create a proprietary pipeline including bispecific T-cell engagers and antibody-drug conjugates. Genmab aims to transform the lives of people with cancer and other serious diseases by 2030.
YTD Price Performance: -0.33%
Average Trading Volume: 1,477,447
Technical Sentiment Signal: Buy
Current Market Cap: $13.02B
Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.